• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    908 Devices Appoints Jeff George and Fenel Eloi to its Board of Directors

    2/23/21 8:00:00 AM ET
    $MASS
    $AMRX
    Industrial Machinery/Components
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MASS alert in real time by email

    BOSTON--(BUSINESS WIRE)--908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it has appointed Jeff George and Fenel Eloi to serve on its Board of Directors, effective immediately.

    Mr. George brings more than two decades of global healthcare and corporate leadership experience across North America, Europe, and emerging markets. He served as the global division head and CEO of two $10 billion divisions of Novartis, Sandoz and Alcon, between 2008 and 2016, where in parallel he served on the Novartis Group executive committee. He also serves on the board of directors of Amneal Pharmaceutical (NYSE: AMRX), Dorian Therapeutics, and Wishbone Medical.

    Fenel Eloi is a highly seasoned life science executive experienced in leading the transformation of small and mid-size companies to large operating global organizations. Mr. Eloi served as the CFO and then COO at Cell Signaling Technology, a bio reagents company, where he provided leadership in the transformation of the company to a global operation, between 2006 and 2018. He also serves on the board of directors of MitoTherapeutix, a privately held drug development biotech company.

    “We are delighted to welcome Jeff and Fenel to 908 Devices’ Board of Directors. Jeff brings extensive experience in executive roles in the pharmaceutical market on a global scale, and Fenel has extensive finance and operational experience successfully scaling companies through high growth periods,” said Kevin Hrusovsky, Chairman of 908 Devices.

    “I am honored to join the Board of Directors for 908 Devices, an innovative, high-growth company democratizing laboratory mass spectrometry with simple handheld and desktop devices which address critical-to-life applications,” said Mr. George. “I look forward to partnering with the Company’s talented leadership team as they continue to further develop their technology by reducing size and increasing analyte panels and capabilities to simplify the sample to answer process for customers.”

    “I’m very excited for the opportunity to support 908 Devices in scaling up their operations as they make mass spec available to the masses,” said Mr. Eloi. “As we look to the future, I am confident that they are just scratching the surface as to what their proprietary platform can do and at its ultimate market potential.”

    The Company also announced that Prof. J. Michael Ramsey and Sharon Kedar have chosen not to stand for re-election. Prof. Ramsey has been a director of 908 Devices since 2012 and Ms. Kedar since 2019. Both Prof. Ramsey and Ms. Kedar will continue to serve on the Board until the completion of the Annual Meeting of Stockholders in June, at which time Mr. George and Mr. Eloi are expected to stand for re-election to the Board by a vote of the Company’s stockholders.

    “I echo Kevin Hrusovsky’s excitement for Jeff and Fenel joining our Board of Directors. I also want to personally thank both Mike and Sharon for the many contributions they have made,” said Kevin J. Knopp, CEO of 908 Devices. “From the beginning, Mike’s technical acumen has guided our pursuits. He has been a true partner and I look forward to his continuing contributions on our Scientific Advisory Board where he will serve as Co-Chair with our CTO, Dr. Christopher D. Brown. I am grateful to our board for their guidance and partnership. Over the coming months, we will continue to evaluate additional board candidates to further strengthen our board and add increased diversity.”

    About 908 Devices
    908 Devices is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics, and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation, and machine learning. To learn more about 908 Devices, visit: https://908devices.com/.

    Forward Looking Statements
    This press release includes “forward looking statements,” including with respect to the composition of the Company’s Board of Directors. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the SEC which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

    Get the next $MASS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASS
    $AMRX

    CompanyDatePrice TargetRatingAnalyst
    Amneal Pharmaceuticals Inc.
    $AMRX
    6/6/2025$12.00Buy
    Goldman
    Amneal Pharmaceuticals Inc.
    $AMRX
    2/24/2025$9.00 → $12.00Neutral → Overweight
    Analyst
    908 Devices Inc.
    $MASS
    11/13/2024$12.00 → $4.00Outperform → Market Perform
    Leerink Partners
    Amneal Pharmaceuticals Inc.
    $AMRX
    9/6/2024$9.00Underweight → Neutral
    JP Morgan
    908 Devices Inc.
    $MASS
    2/7/2023$14.00Overweight
    Stephens
    908 Devices Inc.
    $MASS
    3/8/2022$40.00 → $30.00Outperform
    SVB Leerink
    908 Devices Inc.
    $MASS
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $MASS
    $AMRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Asylon Robotics and 908 Devices Deliver Robotic Security at the 2025 Indianapolis 500

      Autonomous Ground Security Robots with Real-Time Gas Detection Deployed to Safeguard the World's Largest Single-Day Sporting Event Asylon, the U.S. leader in robotic security solutions, in collaboration with 908 Devices, the Indianapolis Metropolitan Police Department, and the Indianapolis Motor Speedway, returned to this year's Indianapolis 500 to deploy its gas-sniffing security robots to help increase the safety and security of those attending the largest single-day sporting event in the world. More than 300,000 people attended this year's event, and Asylon's solution provided unprecedented real-time situational awareness and detection capabilities to the emergency operations center. T

      6/25/25 8:03:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences

      Amneal holds exclusive U.S. commercialization rights; BLA filing expected in Q4 2025 Poised to be among the first wave of biosimilars in the $3.9 billion U.S. omalizumab market and an important growth driver for Amneal BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today highlighted positive topline results from a confirmatory clinical efficacy and safety clinical trial evaluating ADL-018, a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. The randomized, double-blind, multicenter study was conducted by Kashiv to assess the efficacy, safety, and immunogenicity of ADL-018 compare

      6/25/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials

    $MASS
    $AMRX
    Leadership Updates

    Live Leadership Updates

    See more
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness Month

      Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global biopharmaceutical company, today announced donations totaling $1.5 million to multiple patient assistance foundations that support individuals living with Parkinson's disease in honor of Parkinson's Awareness Month. These contributions underscore Amneal's ongoing commitment to the Parkinson's community by supporting patient care, education, and advocacy—and helping patients and caregivers navigate the unique challenges of living with the disease. Parkinson's disease affects more than 10 million people around the world. The progressive nature of the disease, along with the cost of treatment, often places signif

      4/11/25 8:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms. Leonhart brings a deep understanding of our customers in law enforcement and adjacent markets. Her 34-year career in the DEA encompassed various positions with increasing levels of responsibility, including Special Agent in Charge of the Los Angeles Field Division from 1998 to 2003, Deputy Administrator (nominated by President Bush) from 2003 to 2007, Acting Administrator from 2007 to 2010, and Admini

      6/25/24 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    $AMRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 5:11:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 908 Devices Inc.

      SC 13G/A - 908 Devices Inc. (0001555279) (Subject)

      11/14/24 4:25:10 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Amneal Pharmaceuticals Inc.

      SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)

      11/14/24 4:11:34 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MASS
    $AMRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Goldman initiated coverage on Amneal Pharmaceuticals with a new price target

      Goldman initiated coverage of Amneal Pharmaceuticals with a rating of Buy and set a new price target of $12.00

      6/6/25 8:33:10 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amneal Pharmaceuticals upgraded by Analyst with a new price target

      Analyst upgraded Amneal Pharmaceuticals from Neutral to Overweight and set a new price target of $12.00 from $9.00 previously

      2/24/25 7:02:03 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 908 Devices downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 908 Devices from Outperform to Market Perform and set a new price target of $4.00 from $12.00 previously

      11/13/24 8:05:47 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    $AMRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Brown Christopher D. claimed ownership of 962,122 shares (SEC Form 3)

      3 - 908 Devices Inc. (0001555279) (Issuer)

      6/18/25 4:37:18 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Chief Legal & Admin Officer Turner Michael S. sold $184,789 worth of shares (24,603 units at $7.51), closing all direct ownership in the company (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      6/18/25 4:35:24 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Director Patel Gautam sold $761,146 worth of shares (94,906 units at $8.02), decreasing direct ownership by 6% to 1,609,144 units (SEC Form 4)

      4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)

      6/18/25 4:11:43 PM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MASS
    $AMRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Knopp Kevin J. bought $66,596 worth of shares (15,000 units at $4.44), increasing direct ownership by 2% to 722,733 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/19/25 4:37:42 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Director Spoto Mark bought $42,850 worth of shares (10,000 units at $4.29), increasing direct ownership by 19% to 62,971 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/15/25 4:52:08 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • President and CEO Knopp Kevin J. bought $64,788 worth of shares (15,000 units at $4.32), increasing direct ownership by 2% to 707,733 units (SEC Form 4)

      4 - 908 Devices Inc. (0001555279) (Issuer)

      5/14/25 4:28:02 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    $AMRX
    SEC Filings

    See more
    • 908 Devices Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - 908 Devices Inc. (0001555279) (Filer)

      6/16/25 8:30:24 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • 908 Devices Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - 908 Devices Inc. (0001555279) (Filer)

      6/13/25 4:15:38 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • SEC Form 144 filed by 908 Devices Inc.

      144 - 908 Devices Inc. (0001555279) (Subject)

      6/4/25 4:26:43 PM ET
      $MASS
      Industrial Machinery/Components
      Industrials

    $MASS
    $AMRX
    Financials

    Live finance-specific insights

    See more
    • 908 Devices Reports First Quarter 2025 Financial Results and Reiterates 2025 Revenue Outlook

      Revenue from continuing operations grew 59% compared to prior year, driven by an increase in product and service revenue 908 Devices Inc. (NASDAQ:MASS) a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2025. "We are off to a strong start in 2025, with first-quarter revenue exceeding our expectations and the transformation to 908 Devices 2.0 already delivering both top-line growth and meaningful cost reductions," said Kevin J. Knopp, CEO and Co-founder. "With a sharpened focus, a strengthened financial position, and macro trends in

      5/13/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials
    • Amneal Reports First Quarter 2025 Financial Results

      ‒ Q1 2025 Net Revenue of $695 million; GAAP Net Income of $12 million; Diluted Income per Share of $0.04 ‒ ‒ Adjusted EBITDA of $170 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Affirming 2025 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the first quarter ended March 31, 2025. "Amneal delivered another strong quarter to start 2025, with broad-based growth across all three segments driven by our team's outstanding execution. We are very pleased with the commercial uptake of CREXONT® for Parkinson's Disease and the momentum of our recently launched injectable products, which are delivering tremendous value to pat

      5/2/25 6:00:00 AM ET
      $AMRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 908 Devices Announces Preliminary First Quarter 2025 Financial Results

      At least 55% reported revenue growth from continuing operations compared to prior year 908 Devices Inc. (NASDAQ:MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of 2024, reflecting reported growth of approximately 55%. First quarter revenues do not include approximately $1.1 million of additional re

      4/15/25 7:00:00 AM ET
      $MASS
      Industrial Machinery/Components
      Industrials